Further, treatment with Ruxolitinib (JAK2/STAT3 inhibitor) or Trametinib (MEK/ERK1/2 inhibitor) significantly enhanced the response of NB tumors to etoposide[166]. Here, STAT3 is linked to neuroblastoma.